Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
PROCEDURE

endoscopic surgery

The tumor was resected by endoscopic nasopharyngectomy.

DRUG

Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy

Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.

DRUG

Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy

Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.

DRUG

Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy

Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.

Trial Locations (7)

200031

RECRUITING

Eye& ENT Hospital, Fudan University, Shanghai

Unknown

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

RECRUITING

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

NOT_YET_RECRUITING

Changhai Hospital, Shanghai

NOT_YET_RECRUITING

Shanghai Sixth People's Hospital, Shanghai

NOT_YET_RECRUITING

Shanghai Zhongshan Hospital, Shanghai

NOT_YET_RECRUITING

Shenzhen Second People's Hospital, Shenzhen

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Shanghai 6th People's Hospital

OTHER

collaborator

Changhai Hospital

OTHER

collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

People's Hospital of Guangxi Zhuang Autonomous Region

OTHER

collaborator

Shenzhen Second People's Hospital

OTHER

lead

Eye & ENT Hospital of Fudan University

OTHER